AIDS and Behavior

, Volume 21, Issue 7, pp 1825–1835 | Cite as

Direct and Indirect Effects of Heavy Alcohol Use on Clinical Outcomes in a Longitudinal Study of HIV Patients on ART

  • Christopher W. Kahler
  • Tao Liu
  • Patricia A. Cioe
  • Vaughn Bryant
  • Megan M. Pinkston
  • Erna M. Kojic
  • Nur Onen
  • Jason V. Baker
  • John Hammer
  • John T. Brooks
  • Pragna Patel
Original Paper

Abstract

In a cohort of patients receiving care for HIV, we examined longitudinally the impact of past 30-day frequency of heavy drinking (consuming 5+ drinks on one occasion) on HIV-related (detectable viral load and CD4+ T cell count) and non-HIV-related (hemoglobin and biomarkers of kidney function and liver fibrosis) clinical outcomes and the extent to which these effects were due to reduced antiretroviral therapy (ART) adherence. Data came from the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy. Between March 2004 and June 2006, 533 individuals receiving ART were recruited and followed every 6 months for six years. Using longitudinal mediation analysis, we estimated natural direct effects (NDE) of heavy drinking frequency (never, 1–3 times, or 4+ times in the past 30 days) on clinical outcomes and natural indirect effects (NIE) mediated via ART adherence. A one-level increase in heavy drinking frequency had a significant negative NDE on CD4+ T-cell counts (-10.61 cells/mm3; 95 % CI [-17.10, -4.12]) and a significant NIE through reduced ART adherence of -0.72 cells/mm3 (95 % CI [-1.28, -0.15]), as well as a significant NIE on risk of detectable viral load (risk ratio = 1.03; 95 % CI [1.00, 1.05]). Heavy drinking had a significant detrimental NIE on a combined index of 5-year mortality risk and detrimental NDE and total effect on a biomarker of liver fibrosis. Heavy drinking has deleterious effects on multiple clinical outcomes in people living with HIV, some of which are mediated through reduced ART adherence.

Keywords

Alcohol HIV Adherence Viral load Liver function VACS Index 

Notes

Funding

This work was supported by the Centers for Disease Control and Prevention contract numbers 200-2002-00,610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, and 200-2007-23636. Additional support was provided by grant number P01 AA019072 from the National Institute on Alcohol Abuse and Alcoholism, grant number T32 DA016184 from the National Institute on Drug Abuse, and the Lifespan/Tufts/Brown Center for AIDS Research (CFAR) grant number P30 AI042853.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Disclaimer

The findings and conclusions from this review are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Centers for Disease Control and Prevention. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—medical monitoring project, United States, 2013 cycle (June 2013–May 2014). HIV Surveillance Special Report 16. Jan 2016.Google Scholar
  2. 2.
    DeLorenze GN, Weisner C, Tsai AL, et al. Excess mortality among HIV-infected patients diagnosed with substance use dependence or abuse receiving care in a fully integrated medical care program. Alcohol Clin Exp Res. 2011;35:203–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Justice AC, McGinnis KA, Tate JP, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend. 2016;161:95–103.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43:411–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hendershot CS, Stoner SA, Pantalone DW, et al. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005;29(7):1190–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–85.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kalichman SC, Grebler T, Amaral CM, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med. 2013;28(3):399–405.CrossRefPubMedGoogle Scholar
  9. 9.
    Samet JH, Cheng DM, Libman H, et al. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2008;46(2):194–9.CrossRefGoogle Scholar
  10. 10.
    Azar MM, Springer SA, Meyer JP, et al. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Shacham E, Agbebi A, Stamm K, et al. Alcohol consumption is associated with poor health in HIV clinic patient population: a behavioral surveillance study. AIDS Behav. 2011;15(1):209–13.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Marcellin F, Lions C, Winnock M, et al. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician’s perceptions (HEPAVIH ARNS CO13 cohort). Addiction. 2013;108(7):1250–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Baum MK, Rafie C, Lai S, et al. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retrovir. 2010;26(5):511–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of ‘‘non-HIV’’biomarkers. HIV Med. 2009;11:143–51.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563–72.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Justice, AC, Freiberg, MS, Tracy, R, the VACS Project team et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012;54(7):984–94.CrossRefGoogle Scholar
  17. 17.
    Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62(2):149–63.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wang EA, McGinnis KA, Long JB, et al. Incarceration and health outcomes in HIV-infected patients: the impact of substance use, primary care engagement, and antiretroviral adherence. Am J Addiction. 2015;24(2):178–84.CrossRefGoogle Scholar
  19. 19.
    Carton JA, Collazos J, de la Fuente B, et al. Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV. Antivir Ther. 2011;16(1):27–35.CrossRefPubMedGoogle Scholar
  20. 20.
    Fuster D, Tsui JI, Cheng DM, et al. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res. 2013;37(9):1527–35.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Muga R, Sanvisens A, Fuster D, et al. Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One. 2012;7(10):e46810.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lim JK, Tate JP, Fultz SL, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis. 2014;58(10):1449–58.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chaudhry AA, Sulkowski MS, Chander G, et al. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009;10(3):133–42.CrossRefPubMedGoogle Scholar
  24. 24.
    Tsui JI, Cheng DM, Libman H, et al. Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C. J Stud Alcohol Drugs. 2013;74(2):266–70.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Blackard JT, Welge JA, Taylor LE, et al. HIV mono-infection is associated with FIB-4—A noninvasive index of liver fibrosis—in women. Clin Infect Dis. 2011;52(5):674–80.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Schaeffner ES, Kurth T, de Jong PE, et al. Alcohol consumption and the risk of renal dysfunction in apparently healthy men. Arch Intern Med. 2005;165:1048–53.CrossRefPubMedGoogle Scholar
  27. 27.
    Funakoshi Y, Omori H, Onoue A, et al. Association between frequency of drinking alcohol and chronic kidney disease in men. Environ Health Prev Med. 2012;17(3):199–204.CrossRefPubMedGoogle Scholar
  28. 28.
    Milman N, Pedersen AN. Blood haemoglobin concentrations are higher in smokers and heavy alcohol consumers than in non-smokers and abstainers: should we adjust the reference range? Ann Hematol. 2009;88(7):687–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Whitehead TP, Clarke CA, Bayliss RI, et al. Mean red cell volume as a marker of alcohol intake. J R Soc Med. 1985;78(10):880–1.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Vellozzi C, Brooks J, Bush T, and the SUN Study Investigators et al. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN.Study). Am J Epidemiol. 2009;169(5): 642–52.Google Scholar
  31. 31.
    Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefPubMedGoogle Scholar
  32. 32.
    Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–83.CrossRefPubMedGoogle Scholar
  34. 34.
    Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282(18):1737–44.CrossRefPubMedGoogle Scholar
  35. 35.
    Valeri L, VanderWeele TJ. Mediation analysis allowing for exposure–mediator interactions and causal interpretation: Theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18(2):137–50.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lange T, Hansen JV. Direct and indirect effects in a survival context. Epidemiology. 2011;22(4):575–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Imai K, Keele L, Yamamoto T. Identification, inference and sensitivity analysis for causal mediation effects. Stat Sci. 2010;25(1):51–71.CrossRefGoogle Scholar
  38. 38.
    VanderWeele TJ. Marginal structural models for the estimation of direct and indirect effects. Epidemiology. 2009;20(1):18–26.CrossRefPubMedGoogle Scholar
  39. 39.
    Pearl, J. Direct and indirect effects. In: Proceedings of the seventeenth conference on uncertainty in artificial intelligence. 2001: pp. 411–20.Google Scholar
  40. 40.
    Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992;13(2):143–55.CrossRefGoogle Scholar
  41. 41.
    Little RJ, Rubin DB. Statistical analysis with missing data. Hoboken: Wiley; 2002.CrossRefGoogle Scholar
  42. 42.
    Daniels MJ, Hogan JW. Missing data in longitudinal studies: Strategies for Bayesian modeling and sensitivity analysis. Boca Raton: Chapman and Hall/CRC Press; 2008.Google Scholar
  43. 43.
    Pellowski JA, Kalichman SC, Kalichman MO, Cherry C. Alcohol-antiretroviral therapy interactive toxicity beliefs and daily medication adherence and alcohol use among people living with HIV. AIDS Care. 2016:1–8.Google Scholar
  44. 44.
    Eken A, Ortiz V, Wands JR. Ethanol inhibits antigen presentation by dendritic cells. Clin Vaccine Immunol. 2011;18(7):1157–66.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Szabo G, Mandrekar P, Dolganiuc A, Catalano D, Kodys K. Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels. Alcohol Clin Exp Res. 2001;25(12):1766–72.PubMedGoogle Scholar
  46. 46.
    Barr T, Helms C, Grant K, Messaoudi I. Opposing effects of alcohol on the immune system. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:242–51.CrossRefPubMedGoogle Scholar
  47. 47.
    Fuster D, Cheng DM, Quinn EK, et al. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014;109(1):62–70.CrossRefPubMedGoogle Scholar
  48. 48.
    Skjelbakken T, Wilsgaard T, Forde OH, et al. Haemoglobin predicts total mortality in a general young and middle-aged male population. The Tromso Study. Scand J Clin Lab Invest. 2006;66(7):567–76.CrossRefPubMedGoogle Scholar
  49. 49.
    Hasin DS, Aharonovich E, O’Leary A, et al. Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement. Addiction. 2013;108(7):1230–40.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Chander G, Hutton HE, Lau B, Xu XQ, McCaul ME. Brief intervention decreases drinking frequency in hiv-infected, heavy drinking women: Results of a randomized controlled trial. JAIDS. 2015;70(2):137–45.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Christopher W. Kahler
    • 1
  • Tao Liu
    • 2
  • Patricia A. Cioe
    • 1
  • Vaughn Bryant
    • 3
  • Megan M. Pinkston
    • 4
  • Erna M. Kojic
    • 5
  • Nur Onen
    • 6
  • Jason V. Baker
    • 7
  • John Hammer
    • 8
  • John T. Brooks
    • 9
  • Pragna Patel
    • 10
  1. 1.Center for Alcohol and Addiction StudiesBrown University School of Public HealthProvidenceUSA
  2. 2.Center for Statistical SciencesBrown University School of Public HealthProvidenceUSA
  3. 3.Department of Clinical and Health PsychologyUniversity of FloridaGainesvilleUSA
  4. 4.Department of Psychiatry and Human BehaviorAlpert Medical School of Brown UniversityProvidenceUSA
  5. 5.Department of Infectious DiseaseBrown UniversityProvidenceUSA
  6. 6.Washington University School of MedicineSt. LouisUSA
  7. 7.Division of Infectious Diseases, Hennepin County Medical CenterUniversity of MinnesotaMinneapolisUSA
  8. 8.Denver Infectious Disease ConsultantsDenverUSA
  9. 9.Division of HIV/AIDS PreventionCenters for Disease Control and PreventionAtlantaUSA
  10. 10.Division of Global Health ProtectionCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations